Nedocromil sodium is a nonsteroidal anti-inflammatory drug used to control asthmatic attacks. Our hypothesis is that nedocromil sodium inhibits virus-induced airway inflammation, a common trigger of asthma. We nebulized nedocromil sodium into beagle dogs (n = 10, mean &plusmn; SEM ages: 149 & p l u s m n ; 13 days) before and after inoculation with canine adenovirus type 2 (CAV2). Control dogs (n = 10) received saline aerosols and were either infected with CAV2 (Sa1/CAV2, n = 7, mean &plusmn; SEM ages: 140 & p l u s m n ; 11 days) or were not infected (Sal/Sal, n = 3, ages: 143 &plusmn; 0 days). All dogs were anesthetized with choralose (80 mg/kg IV), intubated, and mechanically ventilated. Pulmonary function tests and bronchoalveolar lavage (BAL) were performed using standard techniques. Pulmonary function tests revealed no significant change between the nedocromil sodium and non-nedocromil-treated groups. The percentage of infected bronchioles was quantitated as the number of inflamed airways of 40 bronchioles examined times 100 for each dog. Nedocromiltreated dogs had significantly (p < 0.05) less mucosal inflammation (mean &plusmn; SEM, 39% &plusmn; 5%), epithelial denudation (36% &plusmn; 5%), and BAL neutrophilia (11 &plusmn; 3) than did Sal/CAV2 dogs (51% &plusmn; 6%, 57% &plusmn; 4%, and 33% &plusmn; 8%, respectively). We concluded that pretreatment with nedocromil sodium aerosols attenuated CAV2-induced airway inflammation in these beagle puppies.
INTRODUCTION
Nedocromil sodium is a nonsteroid anti-inflammatory agent with proven clinical efficacy for control of acute asthmatic attacks associated with symptomatic viral respiratory infections (12) . Although asthmatic children treated with nedocromil sodium have the same incidence of acute viral respiratory infections and exacerbation of asthmatic symptoms as untreated children, nedocromil sodium-treated patients have significantly more symptom-free days, better peak expiratory flows, and less severe asthma attacks, daytime asthma, and cough than controls (12) . In addition, nedocromil sodium-treated asthmatic patients reduce their need for rescue-inhaled beta2-agonists and have a more rapid resolution of asthma symptoms following respiratory infections (12) . The mechanisms of the protective effects of nedocromil sodium are not well understood.
Because acute airway hyperresponsiveness and inflammation are major components of asthmatic attacks (12, 21, 23) , we postulated that treatment with nedocromil sodium might attenuate the symptoms of virus-induced asthmatic attacks by inhibiting airway inflammatory responses in these patients. In past studies, acute canine adenovirus type 2 (CAV2) infections were associated with bronchial hyperresponsiveness and bronchiolitis in beagle dogs (8, 22) . Thus, we wanted to determine if preand posttreatment with inhaled nedocromil sodium attenuated CAV2-induced bronchiolar inflammation in dogs.
Nebulized nedocromil sodium reduced the severity of mucosal inflammation, airway epithelial denudation, and bronchoalveolar lavage neutrophilia associated with CAV2-induced airway inflammation.
MATERIALS AND METHODS
Our protocols were approved by the University of Arizona Laboratory Animal Care Committee in accordance with National Institutes of Health guidelines (Guide for the Care and Use of Laboratory Animals, NIH Publication No. 86-23). We obtained beagle puppies from a single outbred colony at the Lovelace Respiration Institute (Albuquerque, NM). Care of the puppies and procedures while at Inhalation Toxicology Research Institute (ITRI) were under the supervision of Drs Muggenburg and Bice and were approved by the ITRI Research Committee. The bitches were routinely immunized at only 5 weeks of age against distemper, rabies, CAV2, hepatitis, and canine parainfluenza type 2 to reduce antibody titers in the puppies. These specific-pathogen-free dogs were raised in strict isolation and immunized against distemper, rabies, and hepatitis only at 5-6 weeks of age. They were transported to Tucson and quarantined for approximately 2 weeks prior to these studies.
Protocol. Twenty beagle dogs (110-203 days old) were assigned arbitrarily to 1 of 3 experimental groups: saline/saline (Sal/Sal, n = 3), saline/CAV2 (Sal/CAV2, n = 7), or nedocromil/CAV2 (Ned/CAV2, n = 10). The Sal/CAV2 and Ned/CAV2 groups were inoculated with CAV2 on study day 0. Physical examinations were performed daily on all dogs, and all dogs were assigned a clinical score for symptoms using established protocols as described previously (8, 15, 22) . The severity of the symptoms (cough, stridor, hoarseness, rhinitis, dyspnea, wheezing, and conjunctivitis) were scored as normal (0), mild (1), moderate (2), or severe (3) . The sum of scores (maximum = 21 ) represents the severity of their clinical disease. Weight and rectal temperature were also recorded daily.
Aerosolized nedocromil sodium or saline were delivered twice daily. We used an ultrasonic nebulizer (PulmoSonic Model 25, DeVilbiss Co, Somerset, PA), which delivered 0.3-0.35 ml/min of aerosol particles (mean mass aerodynamic diameter = 1.2 f.1m) with 75% of the particles between 0.5 and 2.0 f.1m as determined by a cascade impactor. The dogs were placed in a holding frame designed for inhalation studies by Muggenburg et al (18) . This frame allowed them to stand comfortably with their chins supported by a harness device. Aerosolized nedocromil sodium was administered with a dog resuscitation mask attached to the nebulizer circuit. This mask adds dead space for rebreathing, and carbon dioxide concentrations (PetC02) increase to 45-50 mmHg. The dogs responded with slow deep breathing, which is sustained for 30-40 minutes of the nebulization period without further increases in PetC02. With this technique, 10-12% of the aerosolized nedocromil sodium was deposited in peripheral airways of the dogs (25) .
Beginning 3 days prior and 3-5 days after inoculation with CAV2 on day 0, each group received twice daily aerosol treatments with saline or nedocromil sodium about 4 hours apart. Ned/CAV2 dogs received nedocromil sodium (0.5% solution in normal saline) as 10 mg in 2 ml of sodium chloride/purified water (isotonic solution), pH adjusted with hydrochloric acid to pH 3.5-5.5.
Sal/Sal and Sal/CAV2 dogs received an aerosolized saline.
On study days -3, 0, and 3-5, after the clinical assessment, anesthesia was induced with intravenous thiopental sodium (5 mg/kg, Abbott, North Chicago, IL), and the dogs were intubated with a cuffed 4.5-5.0-french endotracheal tube. The endotracheal cuff was inflated with the minimum pressure to prevent leaks, with hyperinflation to twice the tidal volume followed by exhalatory obstruction for 4 seconds. Following intubation, intravenous chloralose (80 mg/kg, Sigma Chemical Co, St Louis, MO) was infused over 5-10 minutes, as described previously (8, 9, 15, 22 ). An esophageal balloon (6 cm long, Young Rubber Co, Trenton, NJ) containing the appropriate volume of air (5) was placed in the midesophagus and positioned at the point where the pressure was the most negative. Nasopharyngeal cultures and studies were performed immediately after induction of anesthesia. Additional doses of chloralose (27 mg/kg) were given as needed to maintain suppression of spontaneous respiration. In previous studies in beagle dogs, repeated intravascular injections of chloralose were not associated with acute or chronic toxicity to the lungs, heart, brain or nerves, liver, or kidneys in beagle dogs (8, 9, 15, 22) .
Pulmonary Function Tests. Pulmonary function tests
(PFTs) were used to measure endpoints using standard methods (5, 8, 9, 15, 20, 22) . The ventilator circuit contained a heated pneumotachograph (Fleisch no. 1, Instru-mentation Associates, New York, NY) coupled with 2 equal sections of polyethylene tubing connected to each side of a differential pressure transducer (Validyne model MP45-14-871) for airflow measurements. The transpulmonary pressure (Ptp) was measured with a transducer (Validyne model MP45-32-871) with the esophageal balloon catheter connected to 1 side and the endotracheal tube connected to the other side. The Ptp and the airflow signals were directed into an 8-channel recorder (model 7758D, Hewlett Packard, Waltham, MA). The signals from the recorder were processed with an NB-MIO-16 A/D card (National Instruments Corp, Austin, TX) integrated by computer (Macintosh IIci) using LabVIEW 2.2 software (National Instruments Corp). The program used the flow and pressure signals and the Von Neergard-Wirz equation to measure lung resistance (RL), dynamic compliance (Cdyn), and tidal volume (VT). Bronchoalveolar Lavage. Bronchoalveolar lavages (BAL) were performed in the supine position during ventilation with a resuscitation bag immediately after completion of baseline PFTs on days -3, 0, and 3-5. A pediatric bronchoscope (Model 3C4, Olympus Optical Co, Melville, NY) was inserted through a T-piece adapter into the endotracheal tube and was wedged into the lateral segment of the right middle lobe. Three 10-ml aliquots of sterile normal saline at room temperature were injected separately and were then suctioned into a single specimen trap (Baxter Health Care Corp, Deerfield, IL) connected to a vacuum source. The dwell time was approximately 2 seconds. The recovery of BAL fluid was 68-90% for each aliquot, and the 3 aliquots were pooled for cell counts and chemical mediator assays. BAL fluid was filtered through 2 layers of surgical gauze to remove mucus, if necessary. One aliquot was spun in a cytocentrifuge (Cytospin 2, Shandon Scientific, Sewickely, PA), and the cell pellets were stained with Wright-Giemsa for differential counts. Furthermore, a sample of the BAL fluid was placed in a hemocytometer for total cell counts using standard techniques. Additionally, we measured platelet-activating factor (PAF) in BAL fluid with a l2sl radioimmunoassay kit (NEN Dupont, Wilmington, DE). BAL fluid was extracted using a BOND-ELUT CIs extraction column (Analytichem International, Harbor City, CA). Tumor necrosis factor alpha (TNF-a) bioassay was performed using the WEHI-164 cell line subclone 13 (laboratory of Dr J. L. Waage, Institution of Cancer Research, University of Trondheim, Trondheim, Norway).
Inoculation. After completion of PFTs and BAL on day 0, Sal/CAV2 and Ned/CAV2 dogs were inoculated with the Manhattan strain of CAV2 as previously described (8, 20, 22) . One millilter of inoculum containing 105 TCID50 per milliliter of CAV2 was inoculated intranasally using a small catheter (PE 80) inserted into each nostril and slowly withdrawn during injection. With the catheter in the endotracheal tube, 4 0.25-ml boluses of inoculum also were instilled at the carina. For these installations, the dogs were positioned sequentially in the prone, right decubitus, supine, and left decubitus positions. Following each bolus instillation, 5-7 breaths were FIGURE Scoring system for clinical data. Note increasing severity of infection and infiltrates. delivered using an anesthesia bag. Sal/Sal dogs were inoculated in a similar manner with sterile culture medium.
Pulmonary Histopathology. Dogs were euthanatized for pathology studies on days 3-5, depending on schedule preferences, using an additional injection of thiopental (10 mg/kg) followed by exsanguination. The lungs, airways, and heart were removed en bloc immediately. The lungs were inflated to 25 cm H20 pressure with 10% , neutral buffered formalin and fixed by immersion for 24-72 hours as previously described (8, 15, 20, 22) . The formalin-fixed lungs were sliced parasagittally from each of the 6 lung lobes. Two blocks of tissue (approximately 10 X 5 X 3 mm) from medial and lateral sites from each cut section of each lobe were used for paraffin fixation, for a total of 12 blocks/dog. Four slides/block were made with 5 f.1m of tissue separating each slide specimen. Sections were stained with hematoxylin and eosin. Two trained observers, blinded to the study group, randomly selected slides from the pool of 48 slides/dog. Forty consecutive terminal bronchioles (<2 mm in diameter) with- out alveoli or cartilage in the walls were selected for scoring in each dog.
Terminal bronchioles (X4 magnification) and surrounding parenchymal tissue in each dog were scored for the degree of inflammation of bronchiolar mucosa and peribronchiolar alveoli and for epithelial denudation using a modification of a method previously described (8) . As illustrated in Figure 1 , lung tissue was scored 0-3 for normal, mild, moderate, or severe degrees of inflammation, respectively. As illustrated in Table 1 , the parenchymal tissue was scored 0 if normal or 1, 2, or 3 if 1-10%, 10-50%, or >50%, respectively, of the alveoli adjacent to the airways had inflammatory cells. The degree of peribronchiolar cellularity was also scored 0-3 by visual comparison with the inflammation template illustrated in Figure 1 . Additionally, bronchiolar epithelial denudation was scored 0-3, corresponding to none, mild (1-25%), moderate (25-50%), and severe (>50%), respectively, loss of epithelial tissue from the circumference of the airway. Lung tissue with scores of 0 or 1 were considered free of significant inflammation, whereas scores of 2 or 3 were considered inflamed. The percentage of inflamed airways and parenchyma cellularity or epithelial denudation for each dog was calculated as the number of airways with significant inflammation divided by 40 and multiplied by 100.
Statistical Analysis. Differences among groups for the majority of outcomes were tested using an analysis of variance (ANOVA) on each the 3 test days. Comparisons of data within groups for each day were done with Student's t-tests. Multiple comparisons were conducted using Fisher's PLSD test or the Kruskal-Wallis nonparametric test for ordinal data. Significance was defined at p = 0.05.
RESULTS
Viral nasopharyngeal cultures and serum antibody titers for CAV2 were negative for all groups on days -3 and 0. These tests remained negative for the Sal/Sal group throughout the study period (days [3] [4] [5] . Nasopharyngeal cultures were positive for CAV2 in all dogs in both the Sal/CAV2 and Ned/CAV2 groups on days 3-5, indicating that these dogs were successfully inoculated with CAV2 on day 0. Because all dogs were sacrificed on days 3-5, there are no serum data at later dates for these animals.
As illustrated in Table 2 , age, body weight, clinical scores, body temperature and pulmonary function data on day 0 were not significantly different (p 2': 0.05) among groups. Compared with day 0 data, Sal/Sal dogs increased body weight by 0.3 kg (3.8%) on days 3-5. However, both Sal/CAV2 and Ned/CAV2 groups had significant (p < 0.001) weight loss of 0.6 kg (-9.0% and -7.7%, respectively) on days 3-5 after infection. Both Sal/CAV2 and Ned/CAV2 groups were clinically ill, as indicated by the significant increase (p < 0.001) in clinical scores and body temperature within each group on days 3-5 compared with day 0. Although both infected groups were significantly different from the Sal/Sal dogs, the severity of the total clinical score was trending towards significance (p = 0.06), whereas the scores for both rhinitis and conjunctivitis were significant (p = 0.03 and p = 0.01, respectively) and independent of the cumulative score.
Additionally, as indicated in Table 3 , lung resistance and compliance were not significantly different (p = 0.73 and p = 0.93) among groups on days 3-5, nor were they different within the groups, compared with the values obtained on day 0.
Total cell counts and percentage lymphocytes on day TABLE 3.-Pulmonary function (mean ± SEM) for beagles treated with nedocromil sodium (NED), canine adenovirus 2 (CAV2), and saline (SAL).
Abbreviations: RL = lung resistance to flow; Cdyn = dynamic compliance. 0 were significantly larger (p < 0.05) in the Sal/CAV2 group than in the Ned/CAV2 group, but both were not significantly different from controls (Sal/Sal). However, there was no difference among groups on day 0 for percentage of neutrophils or macrophages. In addition, BAL fluid concentrates of PAF and TNF-a were not significantly different among groups on day 0.
The BAL cell counts were not different among groups on days [3] [4] [5] (Table 4 ), but the Ned/CAV2 dogs had significantly (p < 0.05) increased cell counts on days 3-5 as compared with day 0. However, the Sal/CAV2 dogs had significantly (p ~ 0.05) more neutrophilia in BAL fluid than did the Ned/CAV2 dogs on days 3-5. Furthermore, Sal/CAV2 dogs had a significant increase in neutrophila on days 3-5 as compared with day 0.
Five Sal/CAV2 dogs were euthanatized on day 3, and 2 were euthanatized on day 4. In the Ned/CAV2 group, 5 of 10 were euthanatized on day 3, 2 on day 4, and 3 on day 5. Figures 2 and 3 are representative micrographs of the lung tissue from Sal/CAV2 and Ned/CAV2 dogs. SaIlCAV2 dogs (Figure 2a ) had moderate to severe peribronchiolar and intraluminal inflammatory response and alveolitis. As observed in Figure 2b , the majority of the intraluminal inflammatory cells were neutrophils in direct contact with airway smooth muscle due to extensive epithelial denudation. As illustrated in Figures 3a and 3b , pretreatment with nedocromil sodium was associated with less peribronchiolar and intraluminal inflammation and less epithelial denudation. However, inflamed airways in the Ned/CAV2 dogs also had neutrophilia associated with epithelial denudation. The quantitated degrees of airway mucosal and adjacent parenchymal tissue inflammation and epithelial denudation are shown in Figures 4-6 . Sal/CAV2 dogs had significantly more (p -0.03) mucosal inflammation (mean ± SEM, 61% ± 16%) than did the Ned/CAV2 dogs (41% ± 13%) ( Figure 4 ). Conversely, parenchymal inflammation ( Figure 5 ) was not different (p = 0.77) among these groups. However, parenchymal inflammation ( Figure 5 ) was less than peribronchiolar inflammation ( Figure 4 ) within each group. Ned/CAV2 dogs (31 °70 ± 9%) had significantly less (p = 0.0001) epithelial denudation than did Sal/CAV2 dogs (50% -E-4%).
DISCUSSION
Several studies in our laboratory (8, 14, 22) have demonstrated that susceptible beagle dogs inoculated with TABLE 4.-Bronchoalveolar lavage data (mean ± SEM) for beagles treated with nedocromil sodium (NED), canine adenovirus 2 (CAV2), and saline (SAL). CAV2 develop clinical and histologic evidence of severe bronchiolitis. Our current studies indicate that pretreatment with nedocromil sodium reduces airway inflammation, as indicated by mucosal cellularity scores, BAL fluid neutrophilia, and epithelial denudation in Ned/ CAV2 dogs compared with Sal/CAV2 dogs on days [3] [4] [5] . These studies demonstrate that nedocromil sodium protects against virus-induced lung inflammation. Similar to observations in other studies (8) , acute CAV2 infection in the current study produced bronchiolitis that was heterogeneous in the sense that not all bronchioles were inflamed equally. All lung lobes had an uneven distribution of inflamed bronchioles, but previous studies (8) revealed that CAV2 virons were found in only 4 cell types: alveolar macrophages, alveolar type II cells, polymorphonuclear cells, and ciliated pseudocolumnar epithelial cells (8) .
All of the puppies in the Sal/CAV2 and Ned/CAV2 groups were successfully infected with CAV2, as indicated by cultures for CAV2 and histologic evidence of bronchiolitis. Furthermore, they exhibited symptoms of acute respiratory illness such as weight loss, cough, rhinitis, conjunctivitis, chest wall retractions, prolonged exhalation, and wheezing. Histopathologic studies were performed on days 3-5 because previous studies utilizing CAV2 (8, 22) have shown that the inflammatory responses are most severe from day 3 to day 6 after inoculation.
Pretreatment with nedocromil sodium did not reduce the severity of clinical illness. Cumulative clinical scores, weight loss, and temperature elevations were similar in both Sal/CAV2 and Ned/CAV2 groups, whereas the conjunctivitis score was significantly higher in nedocromiltreated dogs. Konig et al (12) reported similar findings in children with respiratory virus-induced asthmatic attacks treated with nedocromil sodium. Similarly, other anti-inflammatory agents such as systemic steroids decrease virus-induced airway inflammation but impair clearance of the virus from the lung (19) . Perhaps prolonged viral shedding contributes to the severity of clinical illness in spite of reduced inflammation.
Several mechanisms may account for the reduced airway mucosal inflammation and epithelial denudation seen with nedocromil sodium in the present study. Nedocromil sodium inhibits mediator release from mast cells (16) and has anti-inflammatory effects on neutrophils and eosinophils (17) , alveolar macrophages, and platelets (3) . Chitano (4) found that nedocromil sodium significantly reduced the BAL neutrophilia following bronchoprovocation by ozone inhalation in dogs. Previous studies (6) revealed that BAL neutrophilia is highly correlated with the degree of airway mucosal inflammation in beagle dogs with acute CAV2 infection. The Ned/CAV2 group had less BAL neutrophilia and mucosal inflammation than the Sal/CAV2 dogs. Thus, nedocromil sodium reduced the magnitude of neutrophil-induced airway inflammation.
Nedocromil sodium attenuated epithelial denudation in these beagle dogs. Epithelial denudation is a hallmark of viral bronchiolitis and has been described previously in CAV2 (8, 22) , respiratory syncytial virus (7) , and influenza virus (10) infection. Although denudation of infected epithelial cells may represent an important host defense, this pathologic process also may contribute to the development of hyperresponsiveness in airways. Destruction of epithelium may be associated with loss of epithelium-derived relaxing factors (24) or downregulation of neutral endopeptidase (2) , allowing for increased neural peptides at smooth muscle and nerve endings, which may potentially enhance hyperresponsiveness (11) .
The mechanisms by which respiratory viruses induce clinical illnesses are not well understood; however, release of mediators by various target cells may be important (13) . For instance, respiratory infections with adenovirus type 5 in rats is associated with enhanced interleukin (IL)-I, IL-6, and TNF-a production. Alveolar macrophages infected with respiratory syncytial virus (RSV) produce IL-6, IL-8, and TNF-a (1), and infected respiratory epithelium also produces IL-8.
In our current studies, BAL concentrations of PAF and TNF-a in both Sal/CAV2 and Ned/CAV2 groups were not significantly different from those concentrations in the Sal/Sal group. Thus, there is no evidence that concentrations of these mediators were altered by nedocromil sodium inhalation.
Measurements of R, and Cdyn in previous studies (8, 22) have produced varied results. Previously, R, increased, Cdyn decreased, and airway responsiveness to aerosolized histamine increased from day 3 to day 9, as compared with day 0, in CAV2-infected dogs (22) . However, in the study by Grad et al (8) , R, and Cdyn did not change, even at time points greater than those in our current study. We do not know why R, and Cdyn did not change in spite of pathologic evidence of moderate to severe acute bronchiolitis in both studies; however, changes in the physiology may have occurred at a later study date, but dogs in this study were euthanatized on experimental days 3-5. In summary, our data demonstrate that nedocromil sodium, a nonsteroidal anti-inflammatory agent used to control asthma, also attenuates CAV2 airway inflammation and epithelial denudation in dogs. We did not examine viral antigen levels in the Sal/CAV2 or Ned/CAV2 dogs; therefore, we do not know if decreased inflammation in Ned/CAV2 dogs was associated with decreased viral antigen. Further studies are necessary to determine whether inflammation is correlates spatially with en-bAL/t7AL 5~Ll~f;V~.
NtV/C:riV~. hanced viral shedding or, conversely, whether reduced inflammation in these dogs was due partially to decreased CAV2 virus in specific airways.
